Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2446733 | 1.00 | HSD17B10 (0.40) | HSD17B10TDP1ALDH1A1HPGDADRB2 | |
| SCHEMBL2456044 | 0.93 | HSD17B10 (0.41) | HSD17B10TDP1ALDH1A1HPGDADRB2 | |
| SCHEMBL2456042 | 0.93 | HSD17B10 (0.41) | HSD17B10TDP1ALDH1A1HPGDADRB2 | |
| SCHEMBL2449496 | 0.92 | HSD17B10 (0.40) | HSD17B10TDP1ALDH1A1HPGDADRB2 | |
| SCHEMBL2449495 | 0.92 | HSD17B10 (0.40) | HSD17B10TDP1ALDH1A1HPGDADRB2 | |
| SCHEMBL2453633 | 0.91 | HSD17B10 (0.48) | HSD17B10TDP1ALDH1A1HPGDADRB2 | |
| SCHEMBL2453630 | 0.91 | HSD17B10 (0.48) | HSD17B10TDP1ALDH1A1HPGDADRB2 | |
| SCHEMBL2453104 | 0.89 | ALDH1A1 (0.38) | HSD17B10TDP1ALDH1A1HPGDADRB2 | |
| SCHEMBL2453101 | 0.89 | ALDH1A1 (0.38) | HSD17B10TDP1ALDH1A1HPGDADRB2 | |
| SCHEMBL2454877 | 0.85 | TDP1 (0.42) | HSD17B10TDP1ALDH1A1HPGDADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022072-B2 | Azolylmethylidenehydrazine derivative and use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | claimed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | claimed |
| EP-2168951-A1 | AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-31 | — | — | EP | claimed |
| US-8022072-B2 | Azolylmethylidenehydrazine derivative and use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2168951-A1 | AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | ARSA, AHR, HRH2 | HSD17B10 1569/4885TDP1 4865/4885ALDH1A1 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.